A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Sep 2024 Planned primary completion date changed from 30 Oct 2023 to 23 Sep 2024.
13 Sep 2024 Status changed from not yet recruiting to recruiting.
02 Apr 2024 According to Shanghai Junshi Biosciences media release, National Medical Products Administration (NMPA) has accepted two supplemental new drug applications (sNDA) for JS002 for the treatment of heterozygous familial hypercholesterolemia, primary hypercholesterolemia and mixed dyslipidemia, based on this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com